.rll-youtube-player .play{--wpr-bg-41ff87cd-513c-467a-ad04-4daeddd8e465: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Bristol myers squibb bms 986142

Bristol-Myers Squibb (BMS-986142)

Aug 28, 2017

Bruton’s Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target

Bruton's Tyrosine Kinase (BTK) is a cytoplasmic member from the Tec (tyrosine kinase expressed in hepatocellular carcinoma) group of kinases which is engaged with controlling the B cell expansion and is essential in B-lymphocyte advancement, separation, and signaling. Bruton's tyrosine kinase; also known as tyrosine...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles

Feb 12, 2025

Newsletter/Whitepaper

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Bristol-Myers Squibb (BMS-986142)

Bruton’s Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target

Editor Picks